These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17488751)

  • 1. Regression to the mean using the disease activity score in eligibility and response criteria for prescribing TNF-alpha inhibitors in adults with rheumatoid arthritis.
    Greenwood MC; Rathi J; Hakim AJ; Scott DL; Doyle DV
    Rheumatology (Oxford); 2007 Jul; 46(7):1165-7. PubMed ID: 17488751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres.
    Smith N; Gadsby K; Butt S; Carruthers D; Deeming A; Ledingham J; Fletcher M; Mulherin D; Roskell S; Kay L; Nicholl K; Cooper R; Worsley A; Deighton C
    Rheumatology (Oxford); 2007 Oct; 46(10):1557-9. PubMed ID: 17666440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y; Youssef SS; El Gaafary M
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
    Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
    J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes.
    Wolfe F; Michaud K; Pincus T; Furst D; Keystone E
    Arthritis Rheum; 2005 Dec; 52(12):3873-9. PubMed ID: 16320335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.
    Hetland ML; Lindegaard HM; Hansen A; Pødenphant J; Unkerskov J; Ringsdal VS; Østergaard M; Tarp U
    Ann Rheum Dis; 2008 Jul; 67(7):1023-6. PubMed ID: 18272669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
    Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
    J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
    Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
    Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders.
    Buch MH; Bingham SJ; Bryer D; Emery P
    Rheumatology (Oxford); 2007 Jul; 46(7):1153-6. PubMed ID: 17478470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis.
    Radovits BJ; Fransen J; Eijsbouts A; van Riel PL; Laan RF
    Rheumatology (Oxford); 2009 Aug; 48(8):906-10. PubMed ID: 19478038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic.
    Hider SL; Tanveer W; Brownfield A; Mattey DL; Packham JC
    Rheumatology (Oxford); 2009 Sep; 48(9):1152-4. PubMed ID: 19608723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orthopaedic intervention in early rheumatoid arthritis. Occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years.
    James D; Young A; Kulinskaya E; Knight E; Thompson W; Ollier W; Dixey J;
    Rheumatology (Oxford); 2004 Mar; 43(3):369-76. PubMed ID: 14722346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
    Parker A; Izmailova ES; Narang J; Badola S; Le T; Roubenoff R; Ginsburg GS; Maier A; Coblyn JS; Shadick NA; Weinblatt ME
    J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hand function tests are important and sensitive tools for assessment of treatment response in patients with rheumatoid arthritis.
    Eberhardt K; Sandqvist G; Geborek P
    Scand J Rheumatol; 2008; 37(2):109-12. PubMed ID: 18415767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of anti-TNF-alpha efficacy in rheumatoid arthritis: is 3 months sufficient?
    Pocock JM; Vasconcelos JC; Ostör AJ
    Rheumatology (Oxford); 2008 Jul; 47(7):1073-6. PubMed ID: 18503089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis.
    Yazici Y; Krasnokutsky S; Barnes JP; Hines PL; Wang J; Rosenblatt L
    J Rheumatol; 2009 May; 36(5):907-13. PubMed ID: 19332636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
    Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
    Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis.
    McGonagle D; Tan AL; Madden J; Taylor L; Emery P
    Rheumatology (Oxford); 2008 Jun; 47(6):865-7. PubMed ID: 18390581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-reported outcomes during treatment with tumour necrosis factor alpha inhibitors in patients with rheumatoid arthritis.
    Bala SV; Forslind K; Månsson ME
    Musculoskeletal Care; 2010 Mar; 8(1):27-35. PubMed ID: 19899068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.